Goro Healthcare’s Impactful Participation at MEGO 2024 Conference
Goro Healthcare’s Impactful Participation at MEGO 2024 Conference
Goro Healthcare made a significant impact at the 3rd edition of the MEGO 2024 Conference, held at the Le Meridien Hotel in Dubai, where we proudly participated as a Bronze sponsor.
Exhibition Engagement: Our booth in the exhibition area attracted over 100 gynecologists from the UAE, GCC, and other Middle Eastern countries. These interactions facilitated insightful discussions on Cerviron and highlighted the pressing concerns in women's healthcare.
Presentation Highlights: We delivered an engaging presentation on the primary indications of Cerviron to all MEGO participants, emphasizing its importance in addressing key health issues.
Goro Healthcare adds three new products to our portfolio
We are excited to announce a new strategic partnership that expands our portfolio and unique product offering to patients in the Middle East. Through collaboration with our partner Oanis, and European pharmaceutical manufacturer, Lotos Pharma, Goro Healthcare has obtained exclusive distribution and commercialization rights to three new high-value products in Saudi Arabia, United Arab Emirates and Qatar. These include:
Good Sleep Spray: a new spray formulation of melatonin and passiflora, for sleep regulation, designed for faster absorption and effect, than presently available oral solid formulations.
Collaboration with Dr. Suleiman Al Habib Hospital for continuous medical education
Our team was privileged to collaborate with Dr. Boheira El Geyoushi, Consultant Obstetrician, Gynecologist and Reproductive Health at Dr.Suleiman Al Habib’s Fertility Department, and to participate in the “Managing Infertility Together” health conference. With our recent launch of two new and unique Women’s Health products; Cerviron® and Neupausil®, Goro Healthcare is committed to partnering with our key customers to continue to improve access and awareness of vital medications that address under-treated female medical conditions in the region.
Dr. Sulaiman Al Habib HospitalGoro Healthcare launches Cerviron® in the United Arab Emirates
As part of our commitment to introducing novel therapies in Women’s Health to our region, Goro Healthcare is proud to announce the launch of Cerviron® vaginal ovules in the United Arab Emirates. Cerviron® is used to treat multiple gynecological indications, including vaginal infections, cervical erosions, vulvar itching and for pre and postoperative treatment in gynecological surgery.
We are also delighted to announce that Cerviron® has obtained reimbursement approval in
King’s College Hospital Cerviron® Round Table Meeting
As part of Goro Healthcare’s key launch and customer engagement activities for Cerviron®, and upon the successful listing of the product in King’s College Hospital Dubai, we were privileged to hold a round table meeting with the members of the Gynecology Department at the hospital. The discussion was moderated by Dr. Aparna Devi Gumma, Consultant Obstetrician and Gynecologist and Head of Department, and was an incredible opportunity for us to collaborate with and learn from key opinion leaders
Launching the Demophorius portfolio in UAE and Qatar
We are delighted to announce the UAE and Qatar launch of the Demophorius portfolio of CE approved sutures, blood bags, gloves and consumables, in collaboration with our distribution partner Cigalah. With this expansion of our commercialized portfolio, we look forward to continuing to deliver the broad range high quality medical solutions to our customers in both countries.
https://gorohealthcare.com/demophorius-healthcare/
Demophorius Healthcare is a world leading and award-winning provider of medical solutions that has been delivering high quality products via its worldwide distribution network for over